Treatment of Malignant Vertebral Fractures With Percutaneous Balloon Kyphoplasty. (KYPHOK)

March 23, 2015 updated by: Assistance Publique - Hôpitaux de Paris

Assessment of Percutaneous Balloon Kyphoplasty in the Treatment of Malignant Vertebral Fractures (Multiple Myeloma and Osteolytic Metastases) : "Observational Study"

Balloon Kyphoplasty is an alternative to vertebroplasty in the treatment of painful malignant vertebral fractures. This is a mini-invasive percutaneous treatment, aiming to stabilize the vertebral fracture, decrease of pain. This technique also improves patient function. Namely, bedridden patients are often able to resume walking in the days following vertebral cement injection. Advantage of Balloon Kyphoplasty as compared to vertebroplasty is the ability to inject the cement into the diseased vertebral body which shows cortical destruction with lower pressure, thereby possibly reducing cement leakage and related complications.

This is a multicentric, observational prospective study. Patients are evaluated before and after the procedure.

Sixty women or men older than 18 years, with 1 to 3 painful vertebral fracture(s) of malignant origin (due to multiple myeloma or osteolytic vertebral metastasis) will be enrolled. Each patient will be followed during 1 year after the procedure with 7 visits at D-8, D-1, D1, D15, D90, D180, and D360 or until the death of the patient.

The main evaluation outcome is patient self-global satisfaction regarding the procedure on a semi-quantitative satisfaction scale, 15 days after the Balloon Kyphoplasty.

Study Overview

Status

Terminated

Intervention / Treatment

Detailed Description

Vertebral compression fractures (VCF) represent an important source of morbidity in patients presenting osteolytic metastatic or myelomatous vertebral involvement. In addition, cancer treatments may induce osteoporosis with an additional risk of vertebral fractures.

  • Current medical treatments are symptomatic. They do not treat the fracture itself.
  • Vertebroplasty is an interventional radiological technique that consists of injecting, percutaneously, acrylic cement into the fractured vertebra under radiological guidance and local or general anaesthesia, in order to combine two effects: stabilization of the vertebral body fracture and pain reduction.
  • Balloon Kyphoplasty is a variant of vertebroplasty which is performed using the KyphX® System (Medtronic., Sunnyvale, California). Balloon kyphoplasty aims at restore vertebral height of the fractured vertebra using an inflatable balloon prior to inject surgical polymethylmetacrylate (PMMA)cement,into the vertebral body to fix the fracture. It is an expensive technique costing around 4,000 euros for up to 2 vertebrae in the same patient. The surgical technique for the procedure has been described by LIBERMEAN et al: A bilateral approach is usually chosen to insert working cannulas into the posterior part of the vertebral body through a posterior transpedicular approach. In case of limited and asymmetric vertebral destruction, a single unilateral approach may be preferred. Fluoroscopy is used to insert the tools and control the procedure. With reaming tools, two working channels are created and the balloons are inserted. The balloons are available in lengths of 10, 15 and 20 mm.

The two balloons (one on each side) should ideally be centered at middle height between the superior and inferior endplates and in the anterior two-thirds of the vertebral body. Balloon placement into the vertebral body is checked using radiopaque markers at the two extremities of the balloon. Once inserted, the balloons are inflated using visual, volume and pressure control to create a cavity. Inflation is stopped when one of the following inflation endpoints is reached: pressure raised over 400 psi, balloon contacts one of the cortical bone of the vertebra or reaching maximal balloon inflation volume. The balloons are then deflated and removed. The mean balloon inflation volume is 2 to 3ml. The Bone Filler Device, filled before with 1.5 ml of PMMA, is then advanced through the working cannula towards the anterior part of the cavity and cement is slowly extruded by a stainless steel stylet, acting as a plunger. When the amount of cement from the first Bone Filler Device is delivered in the cavity, it is removed and another Bone Filler Device is advanced through the working cannula. This step is repeated till a complete fill of the cavity is obtained. The same procedure is repeated through the other working cannula at the contra-lateral pedicle. Filling of the cavity with highly viscous PMMA is performed under continuous fluoroscopic control.

The aim of this study is to quantify the analgesic and patient function improvement of Balloon Kyphoplasty together with complication types and rate in patients with malignant vertebral fractures due to metastatic disease or multiple myeloma.

Study Type

Interventional

Enrollment (Actual)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Paris, France, 75010
        • Hôpital Lariboisière-service de radiologie ostéoarticulaire
      • Paris, France, 75014
        • Hôpital Cochin - service de radiologie
      • Paris, France, 75018
        • Hopital Bichat -service de radiologie
    • Val de Marne
      • Creteil, Val de Marne, France, 94000
        • Hôpital Henri Mondor - Service de Radiologie

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Male or female, 18 years or older
  2. 1 to 3 vertebral compression fracture(s), between T5-L5, responding to the following criteria:

    • at least 15% loss of vertebral body height (anterior, median or posterior);
    • malignant origin (bone metastases, multiple myeloma, hemopathy) assessed by imaging, including an MRI and a CT-SCAN of less than 4 weeks.
    • Pain or painful deterioration less than 3 months old, related to one or more vertebral fractures with a VAS higher than 50/100 mm when changing position, or higher than 40/100 mm if associated with morphine ≥ 30 mg/day ;
  3. The pain related to the fractured vertebrae is the more prevalent
  4. More than 3 months life expectancy.
  5. Blood Platelets rate more than or equal to 50 000/mm3 within the week before balloon kyphoplasty procedure (after a correct blood transfusion).
  6. Patient must have signed a consent form.
  7. Patient affiliated to social security

Exclusion Criteria:

  1. Patient younger than 18
  2. Impossibility to perform Balloon Kyphoplasty:

    • Technical impossibility to achieve the percutaneous approach to the vertebra to treat.
    • Vertebral pedicle diameter or height of treated vertebra(e) not sufficient regarding balloon kyphoplasty TROCATHETER size. This should be assessed through prescreening MRI and/or CT-Scan
  3. More than three symptomatic vertebral compression fractures in the same vertebral segment.
  4. Patient receiving additional local treatment within 15 days after balloon kyphoplasty procedure (surgery, radiofrequency, radiotherapy).
  5. Patient with primary bone tumors (eg : osteosarcoma) or single solitary plasmocytoma (patients presenting those tumors on other parts of the body, other than VCF are eligible).
  6. Patients presenting sclerotic or mixed vertebral lesions(sclerotic vertebral lesions at another vertebral level are not a contraindication).
  7. Patients with less than 3 month life expectancy
  8. Patient undergoing an experimental anti-cancerous treatment in Phase I evaluated at the same time
  9. Patient having relevant co-morbidities which may interfere with the data management on pain and quality of life.
  10. Patient presenting an inadequate vertebra with Balloon Kyphoplasty.
  11. Patient undergoing an additional treatment other than balloon kyphoplasty for their vertebral fracture.
  12. Patient presenting neurological signs or spinal cord compression or spinal canal narrowing requiring surgical decompression;
  13. Patient with a medical or surgical condition not compatible with balloon kyphoplasty procedure (eg : a non-treated local infection)
  14. Patient having an allergy to the bone cement and/or to the contrast media used during the balloon kyphoplasty procedure.
  15. Pregnant or breast feeding women

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 1
balloon Kyphoplasty
A bilateral approach is chosen to insert working cannulas into the posterior part of the vertebral body through a posterior transpedicular approach.Once inserted, the balloons are inflated using visual, volume and pressure control to create a cavity.The balloons are then deflated and removed. The Bone Filler Device is then advanced through the working cannula towards the anterior part of the cavity and cement is slowly extruded by a stainless steel stylet, acting as a plunger. When the amount of cement from the first Bone Filler Device is delivered in the cavity, it is removed and another Bone Filler Device is advanced through the working cannula.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Percentage of patients having a residual pain of ≤ 35mm on a VAS scale or a 50 % decrease in daily morphine dose at day 15 after Balloon Kyphoplasty compared to day 0 (day of procedure).
Time Frame: day 15
day 15

Secondary Outcome Measures

Outcome Measure
Time Frame
1° Clinical Outcomes:· Pain evaluation using a visual analogic scale
Time Frame: D-8-D-1, D2 to D5, d15, D90, D180; D360
D-8-D-1, D2 to D5, d15, D90, D180; D360
quality of life evaluation (SF 12).
Time Frame: D-8 to D-1, D2 to D5, D15, D90, D180; D360
D-8 to D-1, D2 to D5, D15, D90, D180; D360
Assessment of the pain due to the compression fracture using a VAS scale in the same position as at the inclusion visit (standing or lying down),
Time Frame: D-8 to D-1, D2 to D5, D15, D90, D180; D360
D-8 to D-1, D2 to D5, D15, D90, D180; D360
Assessment of the patient global satisfaction score using a LICKERT Scale,
Time Frame: D-8 to D-1, D2 to D5, D15, D90, D180; D360
D-8 to D-1, D2 to D5, D15, D90, D180; D360
Percentage of patients who estimate than the pain due to the compression has decreased by more than 50% after the procedure,
Time Frame: day 15
day 15
· Percentage of patients who give a positive answer to the following question: "would you agree to undergo a new Balloon Kyphoplasty in case you need it?"
Time Frame: D2 to D5, D15; D90 ; D180; D360
D2 to D5, D15; D90 ; D180; D360
Time elapsed between Balloon Kyphoplasty procedure and patient get up.
Time Frame: D2 to D5; D15;D90
D2 to D5; D15;D90
Resumption of the upright position for patients confined to bed due to their vertebral fracture
Time Frame: D2 to D5; D15
D2 to D5; D15
Local and general complications related to cement leakage at each vertebral level treated.
Time Frame: each visit
each visit
2° Radiological Outcomes: · Modification of the regional kyphosis angle measured by the Traumatic Regional Angle (ART - STAGNARA and NIEDERMANN) for compression fractures of T10 to L5
Time Frame: D2to dJ5-d15-d90.-d180- d360
D2to dJ5-d15-d90.-d180- d360
Modification of the global Thoracic and lumbar kyphosis angles.
Time Frame: D2 to d5 - D15 - D90 - d180 - d360
D2 to d5 - D15 - D90 - d180 - d360
3° Therapeutic Outcomes :· Need for radiation at day 30 after Balloon Kyphoplasty in patient presenting with Multiple Myeloma.
Time Frame: D30
D30

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Jean-Denis LAREDO, M.D.,PR., Assistance Publique - Hôpitaux de Paris
  • Principal Investigator: Antoine FEYDY, M.D., PhD, Assistance Publique - Hôpitaux de Paris

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2007

Primary Completion (Actual)

November 1, 2009

Study Completion (Actual)

November 1, 2010

Study Registration Dates

First Submitted

September 5, 2008

First Submitted That Met QC Criteria

September 5, 2008

First Posted (Estimate)

September 8, 2008

Study Record Updates

Last Update Posted (Estimate)

March 24, 2015

Last Update Submitted That Met QC Criteria

March 23, 2015

Last Verified

November 1, 2014

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Multiple Myeloma

Clinical Trials on balloon kyphoplasty

3
Subscribe